{
	"l1liv0yeText": "Back",
	"l1liv0yfText": "Christensen MC et al.<span class=\"_ _1\"></span> P<span class=\"_ _1\"></span>oster pr<span class=\"_ _1\"></span>esented at<br>ECNP 2021<span class=\"fs4 v2\">1</span>",
	"l1liv0ygText": "RECONNECT<span class=\"_ _1\"></span> is an interventional, open-label study of flexible doses of Brintellix<span class=\"fs21 ws20 v3\">®</span> <br>(10–20 mg) on depressive symptoms in pa<span class=\"_ _1\"></span>tients with severe MDD comorbid with <br>severe GAD<span class=\"_ _1\"></span>.",
	"l1liv0yhText": "Study objective:<span class=\"ffb\"> <span class=\"ff5\">T<span class=\"_ _9\"></span>o assess the effectiveness of Brintellix® 10–20 mg/day on depressive symptoms <br>(primary objective) as well as on anxiety symptoms, functioning,<span class=\"_ _1\"></span> HRQoL,<span class=\"_ _1\"></span> and global clinical impression <br>(secondary objective).</span></span>",
	"l1liv0yiText": "P<span class=\"_ _1\"></span>rimary outcome: <span class=\"ff5\">Change from baseline to week 8 in depressive<br>symptoms (MADRS total score).</span>",
	"l1liv0yjText": "Secondary outcomes:<span class=\"ff5\"> Change from baseline to week 8<br>in anxiety symptoms (HAM-A,<span class=\"_ _1\"></span> HADS-Anxiety), functioning<br>(F<span class=\"_ _1\"></span>AST), HRQoL<span class=\"_ _1\"></span> (Q-LES-Q-long from), clinical global impr<span class=\"_ _1\"></span>ession<br>(CGI-S, CGI-I), and adverse events.</span>",
	"l1liv0ykText": "Key inclusion criteria",
	"l1liv0yqText": "Brintellix® ",
	"l1liv0yrText": "10–20 mg/day (n=100)",
	"l1liv0ysText": "BRIN",
	"l1liv0ytText": "10 mg/",
	"l1liv0yuText": "day",
	"l1liv0yvText": " ",
	"l1liv0ywText": " ",
	"l1liv0yxText": "0<span class=\"_\"> </span>1<span class=\"_ _20\"> </span>4<span class=\"_ _21\"> </span>12<span class=\"_ _22\"></span>-2",
	"l1liv0yyText": "8",
	"l1liv0yzText": " ",
	"l1liv0z2Text": "Week",
	"l1liv0z3Text": "Screening<span class=\"_ _23\"> </span>End of ",
	"l1liv0z4Text": "treatment",
	"l1liv0z5Text": "Safety",
	"l1liv0z6Text": "follow-up",
	"l1liv0z7Text": "CGI, C<span class=\"_ _1\"></span>linical Globa<span class=\"_ _1\"></span>l Impression<span class=\"_ _1\"></span>; FAST<span class=\"_ _1\"></span>, F<span class=\"_ _1\"></span>unc<span class=\"_ _7\"></span>tioni<span class=\"_ _1\"></span>ng As<span class=\"_ _7\"></span>sessment Short T<span class=\"_ _1\"></span>est; GAD, ge<span class=\"_ _1\"></span>neralized a<span class=\"_ _1\"></span>nxiet<span class=\"_ _7\"></span>y disorde<span class=\"_ _1\"></span>r; HAM-A<span class=\"_ _7\"></span>, Hamilto<span class=\"_ _1\"></span>n anxiet<span class=\"_\"> </span>y r<span class=\"_ _7\"></span>ating scor<span class=\"_ _1\"></span>e; HADS, h<span class=\"_ _1\"></span>ospital <br>anxiety and depression s<span class=\"_ _1\"></span>c<span class=\"_ _7\"></span>ale<span class=\"_ _1\"></span>; HRQoL, health-rel<span class=\"_ _1\"></span>ated quality of life<span class=\"_ _1\"></span>; MADRS, Montgo<span class=\"_ _1\"></span>mer<span class=\"_ _7\"></span>y–Åsberg depression rat<span class=\"_ _1\"></span>ing scale; MDD<span class=\"_ _1\"></span>, major d<span class=\"_ _1\"></span>epressive diso<span class=\"_ _1\"></span>rder; MDE, <br>maj<span class=\"_ _1\"></span>or depressive ep<span class=\"_ _1\"></span>isode; Q-LES-Q, quality of life enj<span class=\"_ _1\"></span>oyment &amp; satisfaction questionnai<span class=\"_ _1\"></span>re.",
	"Brintellix_NewAss_73b16b5d3": "<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-18px; margin-bottom:5px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Primary diagnosis of MDD, current MDE for &lt;12 months</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-18px; margin-bottom:5px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Current comorbid GAD diagnosed prior to MDE</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-18px; margin-bottom:5px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> Age ≥18 and ≤65 years</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-18px; margin-bottom:5px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> MADRS total score ≥22 at baseline</div>\n<div style=\"color:#646162; font-size:12px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-18px; margin-bottom:5px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:14px; padding-right:10px;\">•</b> HAM-A score ≥20 at baseline</div>",
	"Brintellix_NewAss_773ba0f51": "<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-18px; margin-bottom:3px;\"><b style=\"color:#5f6a72; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:13px; padding-right:10px;\">•</b> Brintellix<sup style=\"font-size:50%;\">®</sup> 10 mg once daily for the first week</div>\n<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-18px; margin-bottom:3px;\"><b style=\"color:#5f6a72; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:13px; padding-right:10px;\">•</b> The dose will then be increased to 20 mg/day at week</div>\n<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-18px; margin-bottom:3px;\"><b style=\"color:#5f6a72; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:13px; padding-right:10px;\">•</b> Dose can subsequently be decreased back to 10 mg/day at scheduled or unscheduled visits, depending on tolerability/response</div>",
	"Brintellix_NewAss_70b4d7623": "<div style=\"text-align: center; color:#FFF; font-size:9px; font-family: 'b_SCCHXC+AvenirNext-DemiBold';\">BRIN<br><span style=\"font-size:6px; font-family: 'a_SCCHXC+AvenirNext-Medium';\">10 mg/<br>day</span></div>",
	"Brintellix_NewAss_72a8a8b9a": "<div style=\"text-align: center; color:#FFF; font-size:9px; font-family: 'b_SCCHXC+AvenirNext-DemiBold';\">Brintellix®<br><span style=\"font-size:9px; font-family: 'a_SCCHXC+AvenirNext-Medium';\">10–20 mg/day (n=100)</span></div>",
	"Brintellix_NewAss_7c6c3036c": "<span style=\"color: rgb(77, 127, 134); font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_NewAss_776fd33fe": "<font style=\"font-size: 15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>1.</b></font> <font style=\"font-size: 15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\"> Christensen MC et al. Poster presented at ECNP. P.0073. 2021.</font>"
}
